10-Q: Hims & Hers Soars: Revenue Up 73%, Net Income Triples

Hims & Hers Health, Inc. reported robust financial results for Q2 2025, with significant increases in revenue and net income driven by strong subscriber growth and strategic expansion into new offerings.

Summary

• Total revenue for the three months ended June 30, 2025, increased by 73% to $544.8 million, up from $315.6 million in the prior year period.
• Net income for the quarter surged by 220% to $42.5 million, compared to $13.3 million in Q2 2024.
• Gross profit grew by 62% to $416.2 million, though gross margin decreased to 76% from 81% in the prior year, primarily due to newer offerings like GLP-1s having higher product and shipping costs.
• Subscribers increased by 31% year-over-year, reaching over 2.4 million as of June 30, 2025.
• Monthly Online Revenue per Average Subscriber rose by 30% to $74 for Q2 2025.
• GLP-1 offerings generated approximately $190 million in Online Revenue for Q2 2025 and $420 million for the first half of 2025, with a significant majority from personalized doses.
• The company completed the acquisition of manufacturing assets from C S Bio Co. in February 2025 for up to $39.1 million and lab testing services business Trybe Labs for $5.1 million.
• In May 2025, Hims & Hers issued $1.0 billion in 0% convertible senior notes due 2030, with net proceeds of approximately $968.7 million.
• A new $100.0 million share repurchase program was authorized in July 2024, with $65.0 million remaining available as of June 30, 2025.

Sentiment

Score: 8

Explanation: The company demonstrates very strong financial performance with significant revenue and net income growth, robust subscriber expansion, and strategic investments in new offerings and capabilities. While gross margin compression and negative free cash flow are noted, they are largely attributable to strategic growth initiatives and a substantial capital raise, positioning the company for future expansion. Legal proceedings are disclosed but not deemed probable losses. The overall outlook is highly positive for growth-oriented investors.

Positives

• Revenue increased by 73% for the three months ended June 30, 2025, reaching $544.8 million, demonstrating strong top-line growth.
• Net income grew by 220% to $42.5 million in Q2 2025, indicating improved profitability.
• Adjusted EBITDA increased by 109% to $82.2 million for Q2 2025, with Adjusted EBITDA margin improving to 15% from 12%.
• Subscriber count grew by 31% to over 2.4 million, reflecting successful customer acquisition and retention strategies.
• Monthly Online Revenue per Average Subscriber increased by 30% to $74, driven by uptake of personalized offerings, including GLP-1s.
• Strategic acquisitions of manufacturing assets (C S Bio Co.) and a lab testing business (Trybe Labs) are expected to strengthen supply chain and expand capabilities.
• Successful issuance of $1.0 billion in 0% convertible senior notes significantly boosted cash and cash equivalents to $1.1 billion, enhancing liquidity.
• The company established a $175.0 million senior secured revolving credit facility, providing additional financial flexibility with $174.0 million available as of June 30, 2025.

Negatives

• Gross margin decreased to 76% in Q2 2025 from 81% in Q2 2024, primarily due to higher product and packaging costs and shipping costs associated with newer offerings like GLP-1s.
• Free Cash Flow was negative $69.4 million for the three months ended June 30, 2025, and negative $19.4 million for the six months ended June 30, 2025, primarily due to increased investments in property, equipment, intangible assets, and inventory.
• Wholesale Revenue decreased by 10% to $8.0 million in Q2 2025, and by 8% to $17.6 million for the six months ended June 30, 2025.
• Operating expenses increased significantly across all categories, with Technology and Development expenses rising by 103% and Marketing expenses by 50% in Q2 2025.

Risks

• High levels of growth may not be achieved in future periods and may not generate a corresponding improvement in results of operations.
• The company may not be able to maintain its profitability.
• Results of operations and key metrics may fluctuate, potentially failing to meet analyst expectations.
• Inability to expand or maintain the scope of offerings, including products, services, provider quality, and treatable conditions, could materially and adversely affect the business.
• Failure to successfully market to new customers and retain existing ones, or evolving privacy/healthcare laws limiting marketing activities, could harm the business.
• Operating in highly competitive markets with well-established healthcare providers, retailers, pharmaceutical companies, and technology companies with significant resources.
• Failure to effectively maintain, promote, and enhance the brand in a cost-effective manner could harm the business and competitive advantage.
• Dependence on relationships with Affiliated Medical Groups, which are not owned by the company, could lead to adverse effects if disrupted.
• Operating in a highly regulated, dynamic environment with increasing and evolving laws and regulations, particularly in telehealth, pharmacy, and compounding, which can impact supply chain and operations.
• Inability of facilities to obtain/maintain necessary licenses and permits or comply with applicable laws and regulatory requirements.
• Evolving government regulations and enforcement activities may require increased costs or adversely affect results of operations.
• Security breaches, loss of data, and other disruptions could compromise sensitive information, expose the company to liability, and harm its reputation.
• Subject to legal proceedings in the ordinary course of business, including intellectual property disputes or claims related to marketing or product sales, which can be costly to defend.
• May require additional capital to support business growth, which might not be available on acceptable terms, if at all.
• Dual class common stock structure concentrates voting power with the CEO, limiting investor influence.
• The market price of Class A common stock may be volatile.
• Disruption in the global supply chain, supply chain concentration, and changes to tax or trade policy could negatively impact the business.
• The pharmacy business subjects the company to additional healthcare laws and regulations beyond core telehealth, increasing compliance complexity.
• Payments system depends on third-party service providers and is subject to evolving laws and regulations.
• Pricing decisions may adversely affect the ability to attract new customers, providers, and partners, or impact revenue and profitability.
• Dependence on the continuing and collaborative efforts of the management team; loss of services could severely disrupt the business.
• Inability to hire, integrate, develop, motivate, and retain personnel could impede effective growth.
• Significant portion of inventory stored in Ohio and Arizona facilities, and at MedisourceRx, making the business vulnerable to damage or disruption at these locations.
• Failure to comply with anti-bribery, anti-corruption, and anti-money laundering laws could subject the company to penalties.
• Failure to protect or enforce intellectual property rights could harm the business.
• Future claims of intellectual property violations by others are costly to defend and could limit operations.
• Changes in accounting rules, assumptions, or judgments could materially and adversely affect the company.
• Risk of product liability claims and potential inability to maintain or obtain adequate insurance.
• Business could be disrupted by catastrophic events and man-made problems, such as power disruptions, data security breaches, and terrorism.
• Adverse tax laws or regulations could be enacted or existing laws applied, increasing tax liability and costs.
• Certain U.S. state tax authorities may assert state nexus, leading to additional state and local income taxes.
• Reports published by analysts, including projections differing from actual results, could adversely affect stock price and trading volume.

Future Outlook

The company expects to continue focusing on long-term growth by investing in fulfillment, distribution, and operating capabilities, including its affiliated and wholly-owned pharmacies and recently acquired lab testing and peptide manufacturing facilities. Significant investments in marketing to acquire new customers and enhance product offerings are planned, with an increasing focus on personalized solutions. The company anticipates revenue from personalized offerings to increasingly drive Online Revenue growth. While these investments are expected to increase operating expenses in the short term, they are projected to positively impact results of operations in the long term. The company also plans to pursue further acquisitions or investments in complementary businesses and technologies, including its recent acquisition of Zava Global GmbH for international expansion. The company expects interest income to increase in the near term due to significant cash balances, partially offset by interest expense from debt amortization. The company is evaluating the impact of the One Big Beautiful Bill Act on its financial statements, expecting a reduction in current income tax liabilities and an enhancement of near-term cash flows due to tax deferrals.

Management Comments

• Management believes the company has the technical platform, distributed provider network, and access to clinical capabilities to lead the migration of routine office visits to a personalized, digital, accessible format.
• Management's decision to increase investment in display, search, streaming and linear television (including a Super Bowl marketing campaign), affiliate, and radio and podcast marketing drove increases in customer acquisition costs.
• Management expects revenue from personalized offerings across the business to increasingly drive Online Revenue growth in the future, and plans to continue to invest in personalized product offerings, including compounding capabilities.
• Management anticipates that investments in fulfillment and operating capabilities will lead to additional operational efficiencies, with revenue growth continuing to outpace these investments, leading to a decrease in operations and support expenses as a percentage of revenue over the long term.
• Management expects General and Administrative expenses to decrease as a percentage of revenue over the long term due to disciplined headcount growth and overall expense management.
• Management believes existing cash resources and the Revolving Credit Facility are sufficient to support planned operations for at least one year past the issuance date of the financial statements.

Industry Context

The company operates in the rapidly evolving and highly competitive telehealth and digital health industries, which are undergoing significant structural change and consolidation. Demand for the company's offerings is driven by rising traditional healthcare costs, access difficulties, patient stigma, and a shift towards patient-centric, personalized healthcare enabled by technology. The company is actively expanding into new health and wellness specialties, including weight loss solutions like GLP-1s, and integrating artificial intelligence, aligning with broader industry trends towards specialized and technology-driven care. The regulatory landscape, particularly concerning compounded medications and telehealth, remains dynamic, posing both opportunities and challenges for market participants.

Management Changes

Legal Proceedings

• Two putative securities class action lawsuits (Sookdeo v. Hims & Hers Health, Inc., et al. and Yaghsizian v. Hims & Hers Health, Inc., et al.) were filed on June 25, 2025, alleging securities law violations related to alleged misrepresentations about the company's business, operations, prospects, and relationship with Novo Nordisk. The company does not currently consider a loss on these lawsuits to be probable.
• Two putative shareholder derivative lawsuits (Jones v. Dudum, et al. and Herman v. Dudum, et al.) were filed on July 14, 2025, and July 29, 2025, respectively, against certain directors and executives, relating to the matters alleged in the securities actions and alleging breaches of fiduciary duty. The company is a nominal defendant and does not currently consider a loss on these lawsuits to be probable.
• The Federal Trade Commission (FTC) issued a Civil Investigative Demand in October 2023 as part of a non-public investigation. The FTC has not communicated any potential conclusions or findings, and the company does not expect a material impact on its business or operations.

Related Party Transactions

• Payments of $1.3 million for Q2 2025 and $2.7 million for H1 2025 were made to Woolly Labs, Inc. (d/b/a Vouched) for identity verification services. Vouched is no longer considered a related party as of July 1, 2025, due to an executive leadership change at the company.

Stakeholder Impact

• Shareholders: Significant revenue and net income growth, coupled with strategic acquisitions and a successful capital raise, could positively impact share price. However, dilution from convertible notes and potential stock price volatility are noted risks. The new share repurchase program could provide support.
• Employees: Continued growth and expansion into new areas (e.g., lab testing, peptide manufacturing, international markets) will likely lead to increased headcount and opportunities. Stock-based compensation remains a significant component of overall compensation.
• Customers: Expansion of offerings, including personalized solutions and GLP-1s, aims to provide broader access to health and wellness treatments. Investments in fulfillment and technology are intended to improve customer experience and service quality. However, regulatory changes regarding compounded GLP-1s could constrain access to certain offerings.
• Suppliers/Partners: Acquisitions like C S Bio Co. and MedisourceRx aim to strengthen the supply chain and internal fulfillment capabilities, potentially shifting reliance from third-party suppliers. Relationships with Affiliated Medical Groups and Partner Pharmacies remain critical.
• Creditors: The issuance of $1.0 billion in convertible senior notes and the establishment of a $175.0 million revolving credit facility demonstrate access to capital, enhancing the company's financial stability and ability to meet obligations.

Next Steps

• Continue to invest in fulfillment, distribution, and operating capabilities, including affiliated and wholly-owned pharmacies and recently acquired facilities.
• Continue to make significant investments in marketing to acquire new customers.
• Continue to make investments in product offerings and customer experience, enhancing personalized solutions.
• Pursue opportunities to acquire or invest in complementary businesses, services, and technologies, including intellectual property rights, as evidenced by the Zava Global GmbH acquisition.
• Assess the implications of the One Big Beautiful Bill Act on consolidated financial statements and provide further disclosures in subsequent reporting periods.

Key Dates

Recommendation

The company's Q2 2025 results demonstrate exceptional growth, with revenue up 73% and net income tripling year-over-year. This strong performance is underpinned by robust subscriber growth and successful expansion into high-demand areas like GLP-1 weight loss solutions. While gross margins saw a slight decline due to the strategic pricing and higher costs of new offerings, the significant increase in Adjusted EBITDA indicates strong operational leverage. The recent $1.0 billion convertible notes issuance substantially bolsters liquidity, providing ample capital for continued strategic investments in infrastructure, technology, and international expansion (e.g., Zava Global GmbH acquisition). Although the company faces ongoing regulatory scrutiny, supply chain risks, and legal proceedings, management has indicated these are not expected to have a material adverse impact. The overall trajectory points to continued market leadership and strong future growth potential, making it an attractive investment for growth-oriented portfolios.

Keywords

Telehealth, Digital Health, Direct-to-Consumer, GLP-1, Weight Loss, Pharmacy, Compounding, Sexual Health, Mental Health, Dermatology, Subscription Model, SEC Filing, Healthcare Technology, Online Pharmacy